Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple

  • 0 views
  • 05 Mar, 2021
  • 2 locations
Busulfan Melphalan Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)

participants with multiple myeloma who are candidates for autologous stem cell transplantation. To test this hypothesis, the investigators designed a phase I/II trial combining IV busulfan 130 mg/m2 plus

  • 0 views
  • 03 May, 2021
  • 1 location
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-BCMA CAR-T cells for the treatment of multiple myeloma

  • 0 views
  • 31 Jan, 2021
  • 1 location
Carfilzomib Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

multiple myeloma. This portion of the study is complete. This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

platelet count
pomalyst
serum proteins
measurable disease
vasectomy
  • 6 views
  • 28 Jan, 2021
  • 1 location
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.

platelet count
monoclonal antibodies
measurable disease
cancer
neutrophil count
  • 19 views
  • 15 May, 2021
  • 2 locations
Blmf Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.

  • 0 views
  • 26 Mar, 2021
  • 1 location
Belantamab Mafodotin Lenalidomide and Daratumumab for the Treatment of Relapsed Refractory or Previously Untreated Multiple Myeloma

This phase I/II trial studies the best dose and effect of belantamab mafodotin given together with lenalidomide and daratumumab in treating patients with multiple myeloma that has come back

chemotherapy regimen
corticosteroids
dexamethasone
cancer
lenalidomide
  • 0 views
  • 21 Jun, 2021
  • 1 location
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent

dexamethasone
platelet count
lenalidomide
refractory multiple myeloma
  • 0 views
  • 18 Jul, 2021
  • 3 locations
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be Arm A will test bb2121 in combination with CC-220 ( low-dose dexamethasone) Arm B will …

corticosteroids
dexamethasone
measurable disease
bortezomib
  • 0 views
  • 14 Jul, 2021
  • 23 locations
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

  • 0 views
  • 10 Mar, 2021
  • 1 location